Abstract | INTRODUCTION: AIMS: METHODOLOGY: A multicenter dose-response controlled trial was conducted at 110 institutions in Japan from June 1993 to December 1994. Chronic pancreatitis was diagnosed for all patients on the basis of the Japanese criteria for chronic pancreatitis. Two-hundred seven patients were randomized to oral treatment with loxiglumide (300, 600, and 1,200 mg/d) or placebo for 4 weeks. The efficacy of treatment was evaluated on the basis of clinical symptoms, physical signs, and serum pancreatic enzyme levels. The groups were comparable with respect to age, sex, etiology, complications, and previous treatment. RESULTS: The improvement rate of the abdominal and/or back pain was 46% in the loxiglumide 300-mg group, 59% in the 600-mg group, and 52% in the 1,200-mg group, and it was 36% in the placebo group (600 mg versus placebo: p < 0.05). The physical signs evaluated--abdominal tenderness and resistance--improved in all three loxiglumide groups, and the serum pancreatic amylase and trypsin levels decreased significantly in the 600-mg group (p < 0.05). The overall clinical improvement rate was 46% in the 300-mg loxiglumide group, 58% in the 600-mg group, and 52% in the 1,200-mg group, and it was 34% in the placebo group. CONCLUSION:
|
Authors | Keiko Shiratori, Tadashi Takeuchi, Katsusuke Satake, Seiki Matsuno, Study Group of Loxiglumide in Japan |
Journal | Pancreas
(Pancreas)
Vol. 25
Issue 1
Pg. e1-5
(Jul 2002)
ISSN: 0885-3177 [Print] United States |
PMID | 12131781
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Hormone Antagonists
- Receptor, Cholecystokinin A
- Receptors, Cholecystokinin
- loxiglumide
- Lipase
- Amylases
- Trypsin
- Proglumide
|
Topics |
- Acute Disease
- Administration, Oral
- Adult
- Amylases
(blood)
- Chronic Disease
- Female
- Hormone Antagonists
(administration & dosage)
- Humans
- Lipase
(blood)
- Male
- Middle Aged
- Pain
(etiology)
- Pancreatitis
(blood, complications, drug therapy)
- Proglumide
(administration & dosage, analogs & derivatives)
- Receptor, Cholecystokinin A
- Receptors, Cholecystokinin
(antagonists & inhibitors)
- Treatment Outcome
- Trypsin
(blood)
|